177 related articles for article (PubMed ID: 16298826)
41. Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
Leis JF; Primack SL; Schubach SE; Curtin PT; Druker BJ; Maziarz RT
Haematologica; 2004 Sep; 89(9):ECR30. PubMed ID: 15377482
[TBL] [Abstract][Full Text] [Related]
42. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
43. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
Poláková KM; Polívková V; Rulcová J; Klamová H; Jurcek T; Dvoráková D; Zácková D; Pospísil Z; Mayer J; Moravcová J
Exp Hematol; 2010 Jan; 38(1):20-6. PubMed ID: 19837125
[TBL] [Abstract][Full Text] [Related]
44. Hypercalcemia in the blastic phase of chronic myeloid leukemia associated with elevated parathyroid hormone-related protein.
Seymour JF; Grill V; Martin TJ; Lee N; Firkin F
Leukemia; 1993 Oct; 7(10):1672-5. PubMed ID: 8412332
[TBL] [Abstract][Full Text] [Related]
45. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
[TBL] [Abstract][Full Text] [Related]
46. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
47. Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Aftimos P; Nasr F
Leuk Res; 2009 Nov; 33(11):e178-80. PubMed ID: 19446330
[No Abstract] [Full Text] [Related]
48. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Wodarz D
Med Hypotheses; 2008; 70(1):128-36. PubMed ID: 17566666
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
50. Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
Mori T; Yamazaki R; Ikeda Y; Okamoto S
Br J Haematol; 2003 May; 121(4):533. PubMed ID: 12752093
[No Abstract] [Full Text] [Related]
51. Management of early stage disease.
Deininger MW
Hematology Am Soc Hematol Educ Program; 2005; ():174-82. PubMed ID: 16304377
[TBL] [Abstract][Full Text] [Related]
52. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
53. Low concentrations of STI571 in the cerebrospinal fluid: a case report.
Petzer AL; Gunsilius E; Hayes M; Stockhammer G; Duba HC; Schneller F; Grünewald K; Poewe W; Gastl G
Br J Haematol; 2002 Jun; 117(3):623-5. PubMed ID: 12028032
[TBL] [Abstract][Full Text] [Related]
54. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
55. Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
Oku E; Imamura R; Nagata S; Takata Y; Seki R; Otsubo K; Hashiguchi M; Osaki K; Yakushiji K; Yoshimoto K; Ogata H; Sata M; Okamura T
Acta Haematol; 2007; 117(4):191-6. PubMed ID: 17170522
[TBL] [Abstract][Full Text] [Related]
56. [Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship with cytogenetic response].
Zou WY; Xu DR; Su C; Chen M; Li J; Luo SK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Aug; 30(8):1868-70, 1873. PubMed ID: 20813688
[TBL] [Abstract][Full Text] [Related]
57. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
[TBL] [Abstract][Full Text] [Related]
58. Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia.
Pelloso LA; Baiocchi OC; Chauffaille ML; Yamamoto M; Hungria VT; Bordin JO
Eur J Haematol; 2002 Jul; 69(1):58-61. PubMed ID: 12270064
[TBL] [Abstract][Full Text] [Related]
59. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
60. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]